Bisphosphonate-associated osteonecrosis. A clinician's reference to patient management.
Bisphosphonates, as inhibitors of osteoclasts, are widely used in the management of metastatic bone disease and in the prevention of osteomalacia and osteoporosis. Recent cases of bone necrosis of the jaws have been associated with the use of bisphosphonate therapy. A case is presented of a patient with osteonecrosis of the maxilla with a history of long-term bisphosphonate therapy for metastatic breast cancer. The authors treated the patient and suggest appropriate patient management guidelines with reference to current knowledge. Although a definitive treatment for bisphosphonate-associated osteonecrosis has not yet been established, clinicians must be aware of the pharmacologic properties of several bisphosphonates currently available and their indications, susceptible risk factors in the development of osteonecrosis of the jaws, the clinical signs and symptoms, and recommendations for patient management, including prevention and early recognition.
Grewal
Varinder S
VS
St. James Mercy Hospital, Hornell, NY, USA. vgdds@hotmail.com
Fayans
Edgar P
EP
D000369:Aged, 80 and over; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D000891:Anti-Infective Agents, Local / Q000627:therapeutic use; D050071:Bone Density Conservation Agents / Q000009:adverse effects*; D001943:Breast Neoplasms / Q000188:drug therapy; D003646:Debridement; D004164:Diphosphonates / Q000009:adverse effects*; D004198:Disease Susceptibility; D005260:Female; D006801:Humans; D008439:Maxillary Diseases / Q000139:chemically induced*; D015523:Maxillary Sinusitis / Q000150:complications; D010019:Osteomyelitis / Q000150:complications; D010020:Osteonecrosis / Q000139:chemically induced*; D000077268:Pamidronate; D012307:Risk Factors
D000900:Anti-Bacterial Agents; D000891:Anti-Infective Agents, Local; D050071:Bone Density Conservation Agents; D004164:Diphosphonates; D000077268:Pamidronate